Region | Reference | Sample size | Witnessed (%)a | Location: ICU, CCU, OR (%) | Mean age (years)a | Female (%)a | VF/VT (%)a | ROSC (%)a | Survival to hospital discharge (%) a |
---|---|---|---|---|---|---|---|---|---|
Current study | |||||||||
 Total | 900 | 100 | 100 | 57 | 61 | 18 | 55 | 42 | |
 CFA | 450 | 100 | 100 | 57 | 61 | 18 | 67 | 54 | |
 Control | 450 | 100 | 100 | 58 | 60 | 21 | 42 | 28 | |
ANZ b | [51] | 1733 | 80 | NR | NR | 36 | 31 | 46 | 25 |
Austria | [44] | 1041 | NR | 96 | 64 | 37 | 39 | NR | 36c |
Brazil | [38] | 89 | 100 | 100 | 59 | 48 | 15 | 71 | 9 |
China | [49] | 2712 | NR | 7 | 62 | 32 | 57 | 36 | 9 |
Hong Kong | [50] | 431 | 60 | 17 | 71-74d | 38 | 6 | 38 | 5 |
India | [56] | 105 | 100 | 100 | 51 | 25 | 5 | 38 | 1 |
Iran | [7] | Â | Â | Â | Â | Â | Â | Â | Â |
 Total | 80 | 100 | 100 | 61 | 61 | 58 | 54 | NR | |
 CFA | 40 | 100 | 100 | 60 | 55 | 58 | 73 | ||
 Control | 40 | 100 | 100 | 63 | 66 | 58 | 35 | ||
Iran | [36] | 80 | 100 | NR | 67 | 52 | NR | 56 | Â |
Iran | [37] | 600 | NR | 26 | NR | 42 | NR | 45 | 3 |
Iran | [35] | 206 | NR | 31 | 54 | 41 | NR | 20 | 5 |
Ireland | [41] | 741 | 75 | 42 | 66 | 32 | NR | 56 | 18 |
Ireland | [42] | 63 | 87 | 11 | 74 | 37 | NR | 73 | 27 |
Japan | [46] | 491 | 77 | 25 | 71 | 38 | 28 | 65 | 28e |
Norway | [43] | 302 | 85 | 1 | 70 | 36 | NR | 54 | 25 |
Taiwan | [47] | 110 | NR | NR | 67 | 29 | 14 | 67 | 18 |
Taiwan | [48] | 702 | 50 | 21 | 67 | 39 | 88 | 58 | 6 |
Turkey | [45] | 134 | NR | 32 | 67 | 51 | 18 | 49 | 13 |
UAE | [66] | 685 | NR | 46 | 57 | 34 | 9 | 38 | 8 |
USA | [54] | 14,720 | 86 | 51 | 68 | 43 | 25 | 44 | 17 |
USA | [39] | 16,245 | 88 | NR | NR | NR | NR | 52 | 23 |
USA | [59] | 25,006 | 72 | 37 | NR | 42 | 17 | 50 | 15 |
USA | [53] | 84,625 | 100 | 100 | 66 | 42 | 21 | 43 | 17 |
USA | [60] | 471,962 | NR | NR | NR | 48 | NR | NR | 18 |
USA | [40] | 235,959 | NR | NR | 51 | 42 | NR | NR | 30 |